The Value of Real World Evidence (RWE) on the Commercial Side of Pharma and Emerging Markets like India | Realities of RWE Podcast Series | EP01
Real-World Evidence (RWE) is arguably among the most talked about healthcare topics across the life sciences fraternity. While providing innovative solutions to healthcare access challenges using Real-World Data (RWD), Actu-Real is dealing with the challenges of access to RWD and the application of RWE. We thought it would be interesting to unravel the reality behind the hype that’s generated by RWE.
In the spirit of understanding this trend and how it is playing out across various geographies, we have launched our new podcast series titled, “Realities of Real-World Evidence (RWE)”. In this series, we will speak to thought leaders and industry veterans to decode, demystify and decipher not only the science and art behind RWE but also its significance and growing impact in the Pharma industry.
The first episode of this series covers the value of RWE on the commercial side of Pharma and in an emerging market like India. Join Chitra Lele, President and Founder, Actu-Real as she speaks with Dr Viraj Suvarna, Medical Chapter Lead and Chief Medical Officer (ad interim) at Roche Pharma India, on the value that Real-World Evidence (RWE) can offer in emerging markets like India. Dr Viraj will share his perspective and experience with the use of Real World Evidence (RWE) for research and regulatory purposes.
Chitra Lele, Ph.D.
President and Founder, Actu-Real
Dr. Viraj Suvarna
Medical Chapter Lead and Chief Medical Officer (ad interim), Roche Pharma India